Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 80 years old.
- Your breast cancer is ER-positive (at least 50% of cells have hormone receptors) and HER2-negative.
- After surgery, your cancer was found in 1 to 3 lymph nodes (T1–T2 tumor size).
- You have not received chemotherapy, hormone therapy, or radiation before your surgery.
- Your overall health is good with normal blood counts, liver and kidney function (confirmed by blood tests).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.